Summary & Overview
CPT 15017: Skin Cell Suspension Autograft, First 480 sq cm
CPT code 15017 represents the application of a skin cell suspension autograft (SCSA) to complex anatomic sites — including the face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and multiple digits — for the first 480 square centimeters or less. This code captures a specialized reconstructive and dermatologic procedure used in management of extensive skin loss or defects where cell suspension techniques are employed. Nationally, accurate use of this code supports appropriate claims processing, clinical documentation, and utilization tracking for advanced skin reconstruction techniques.
Key payers in the coverage landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides payers' coverage context and identifies common modifier usage where available. Readers will find benchmarks for code utilization, clinical context describing typical indications and sites of service, and notes on documentation elements that support coding and billing. The report also highlights common payer interactions and areas where policy clarification is often needed.
This summary is intended for health system billing leads, coding professionals, and policy analysts seeking a concise national overview of CPT code 15017, its clinical application, and payer considerations.
Billing Code Overview
CPT code 15017 describes the application of a skin cell suspension autograft (SCSA) to the face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and multiple digits. The code applies to the first 480 square centimeters or less of treated surface area.
Service Type: Autograft application — skin cell suspension
Typical Site of Service: Ambulatory surgical centers, hospital outpatient departments, or specialized procedural clinics where dermatologic or reconstructive procedures involving skin cell suspension autografts are performed.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with a full-thickness facial burn and large chronic non-healing wound on the lower face and perioral region undergoes preparation and application of a skin cell suspension autograft (SCSA). The multidisciplinary workflow includes: initial surgical debridement and wound bed preparation under sterile conditions; harvesting a small split-thickness skin sample from a donor site (typically thigh); intraoperative or lab-based processing to create a suspension of autologous skin cells; application of the 15017 SCSA to the prepared facial wound (first 480 sq cm or less); securement with appropriate dressings and, if indicated, temporary graft fixation. Postoperative care includes analgesia, topical antimicrobial dressings, wound checks at regular intervals, and instructions for donor site care. Follow-up visits document graft take, complications (infection, graft loss), and any need for additional reconstructive procedures. Typical facility sites of service are outpatient surgical centers, hospital operating rooms, and occasionally outpatient procedure rooms for select cases; typical providers include plastic surgeons, dermatologic surgeons, and burn surgeons.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the SCSA requires substantially greater work than typical (extensive debridement, unusually complex anatomy). |